Психическое здоровье и сексуальное функционирование женщин с преждевременной недостаточностью яичников

1. Golezar S., Ramezani Tehrani F., Khazaei S., Ebadi A., Keshavarz Z. The global prevalence of primary ovarian insufficiency and early menopause: a meta-analysis. Climacteric. 2019; 22(4): 403-11. https://dx.doi.org/10.1080/13697137.2019.1574738.
2. Rossetti R., Ferrari I., Bonomi M., Persani L. Genetics of primary ovarian insufficiency. Clin Genet. 2017; 91(2):183-98. https://dx.doi.org/10.1111/cge.12921.
3. Денисова В.М., Ярмолинская М.И., Закураева К.А. Преждевременная недостаточность яичников: генетические причины и тактика ведения пациенток (обзор литературы). Журнал акушерства и женских болезней. 2021; 70(3): 75-91.
4. Щагина О.А., Демина Н.А., Бессонова Л.А., Бескоровайная Т.С., Поляков А.В. Мутации гена FOXL2 при синдроме «Блефарофимоз-птоз-обратный эпикант». Медицинская генетика. 2019; 18(8): 17-20.
5. BMS Consensus Statement. Premature ovarian insufficiency (POI). 2023.
6. Kirshenbaum M., Orvieto R. Premature ovarian insufficiency (POI) and autoimmunity-an update appraisal. J. Assist. Reprod. Genet. 2019; 36(11): 2207-15. https://dx.doi.org/10.1007/s10815-019-01572-0.
7. Адамян Л.В., Пивазян Л.Г., Антонова А.А. Преждевременная недостаточность яичников и аутоиммунитет: есть ли взаимосвязь? Проблемы репродукции. 2022; 28(6): 116-24.
8. Ishizuka B. Current understanding of the etiology, symptomatology, and treatment options in premature ovarian insufficiency (POI). Front. Endocrinol. (Lausanne). 2021; 12: 626924. https://dx.doi.org/10.3389/fendo.2021.626924.
9. Panay N., Anderson R.A., Nappi R.E., Vincent A.J., Vujovic S., Webber L. et al. Premature ovarian insufficiency: an International Menopause Society White Paper. Climacteric. 2020; 23(5):426-46. https://dx.doi.org/10.1080/13697137.2020.1804547.
10. Wang Y., Jiang J., Zhang J., Fan P., Xu J. Research progress on the etiology and treatment of premature ovarian insufficiency. Biomed. Hub. 2023; 8(1): 97-107. https://dx.doi.org/10.1159/000535508.
11. ESHRE Guideline: management of women with premature ovarian insufficiency. Hum. Reprod. 2016; 31(5): 926-37. https://dx.doi.org/10.1093/humrep/dew027.
12. Lumsden M.A. The NICE Guideline – Menopause: diagnosis and management. Climacteric. 2016; 19(5): 426-9. https://dx.doi.org/10.1080/13697137.2016.1222483.
13. Baber R.J., Panay N., Fenton A. 2016 IMS Recommendations on women’s midlife health and menopause hormone therapy. Climacteric. 2016; 19(2): 109-50. https://dx.doi.org/10.3109/13697137.2015.1129166.
14. Chon S.J., Umair Z., Yoon M.S. Premature ovarian insufficiency: past, present, and future. Front. Cell. Dev. Biol. 2021; 9: 672890. https://dx.doi.org/10.3389/fcell.2021.672890.
15. Torrealday S., Kodaman P., Pal L. Premature ovarian insufficiency - an update on recent advances in understanding and management. F1000Research. 2017; 6: 2069. https://dx.doi.org/10.12688/f1000research.11948.1.
16. Podfigurna-Stopa A., Czyzyk A., Grymowicz M., Smolarczyk R., Katulski K., Czajkowski K. et al. Premature ovarian insufficiency: the context of long-term effects. J. Endocrinol. Invest. 2016; 39(9): 983-90. https://dx.doi.org/10.1007/s40618-016-0467-z.
17. Upton C.E., Daniels J.P., Davies M.C. Premature ovarian insufficiency: the need for evidence on the effectiveness of hormonal therapy. Climacteric. 2021; 24(5): 453-8. https://dx.doi.org/10.1080/13697137.2021.1902496.
18. Kapoor E. Primary ovarian insufficiency: a toolkit for the busy clinician. Menopause. 2024; 31(1): 65-7. https://dx.doi.org/10.1097/GME.0000000000002275.
19. Shelling A.N., Ahmed Nasef N. The role of lifestyle and dietary factors in the development of premature ovarian insufficiency. Antioxidants. 2023; 12(8): 1601. https://dx.doi.org/10.3390/antiox12081601.
20. Prasad S., Tiwari M., Pandey A.N., Shrivastav T.G., Chaube S.K. Impact of stress on oocyte quality and reproductive outcome. J. Biomed. Sci. 2016; 23(1): 36. https://dx.doi.org/10.1186/s12929-016-0253-4.
21. Fu X.Y., Chen H.H., Zhang N., Ding M.X., Qiu Y.E., Pan X.M. et al. Effects of chronic unpredictable mild stress on ovarian reserve in female rats: Feasibility analysis of a rat model of premature ovarian failure. Mol. Med. Rep. 2018; 18(1): 532-40. https://dx.doi.org/10.3892/mmr.2018.8989.
22. Sun J., Fan Y., Guo Y., Pan H., Zhang C., Mao G. et al. Chronic and cumulative adverse life events in women with primary ovarian insufficiency: an exploratory qualitative study. Front. Endocrinol (Lausanne). 2022; 13. https://dx.doi.org/10.3389/fendo.2022.856044.
23. Gava G., Orsili I., Alvisi S., Mancini I., Seracchioli R., Meriggiola M.C. Cognition, mood and sleep in menopausal transition: the role of menopause hormone therapy. Medicina (B Aires). 2019; 55(10): 668. https://dx.doi.org/10.3390/medicina55100668.
24. Engberg H., Strandqvist A., Nordenström A., Butwicka A., Nordenskjöld A., Hirschberg A.L. et al. Increased psychiatric morbidity in women with complete androgen insensitivity syndrome or complete gonadal dysgenesis. J. Psychosom. Res. 2017; 101: 122-7. https://dx.doi.org/10.1016/j.jpsychores.2017.08.009.
25. Słopień R. Mood disorders in women with premature ovarian insufficiency. Menopausal. Rev. 2018; 17(3): 124-6. https://dx.doi.org/10.5114/pm.2018.78556.
26. Golezar S., Keshavarz Z., Ramezani Tehrani F., Ebadi A., Zayeri F., Golezar M.H. Primary ovarian insufficiency quality of life scale (POIQOLS): development and psychometric properties. BMC Womens Health. 2022; 22(1): 481. https://dx.doi.org/10.1186/s12905-022-02008-1.
27. Xi D., Chen B., Tao H., Xu Y., Chen G. The risk of depressive and anxiety symptoms in women with premature ovarian insufficiency: a systematic review and meta-analysis. Arch. Womens Ment. Health. 2023; 26(1): 1-10. https://dx.doi.org/10.1007/s00737-022-01289-7.
28. Schmidt P.J., Luff J.A., Haq N.A., Vanderhoof V.H., Koziol D.E., Calis K.A. et al. Depression in women with spontaneous 46, XX primary ovarian insufficiency. J. Clin. Endocrinol. Metab. 2011; 96(2): E278-87. https://dx.doi.org/10.1210/jc.2010-0613.
29. Allshouse A.A., Semple A.L., Santoro N.F. Evidence for prolonged and unique amenorrhea-related symptoms in women with premature ovarian failure/primary ovarian insufficiency. Menopause. 2015; 22(2):166-74. https://dx.doi.org/10.1097/GME.0000000000000286.
30. Аверкова В.Г., Юренева С.В. Оценка качества жизни пациенток с преждевременной недостаточностью яичников, принимающих заместительную гормональную терапию. Акушерство и гинекология. 2023; 5: 50-8.
31. Maciejewska-Jeske M., Szeliga A., Męczekalski B. Consequences of premature ovarian insufficiency on women’s sexual health. Menopausal. Rev. 2018; 17(3): 127-30. https://dx.doi.org/10.5114/pm.2018.78557.
32. Nappi R.E., Cucinella L., Martini E., Rossi M., Tiranini L., Martella S. et al. Sexuality in premature ovarian insufficiency. Climacteric. 2019; 22(3): 289-95. https://dx.doi.org/10.1080/13697137.2019.1575356.
33. Calik-Ksepka A., Grymowicz M., Rudnicka E., Skórska J., Machura P., Pięta W. et al. Signs and symptoms, evaluation, and management of genitourinary tract consequences of premature ovarian insufficiency. Menopausal. Rev. 2018; 17(3): 131-4. https://dx.doi.org/10.5114/pm.2018.78558.
34. Paschou S.A., Athanasiadou K.I., Hafford-Letchfield T., Hinchliff S., Mauskar M., Rees M. et al. Sexual health and wellbeing and the menopause: An EMAS clinical guide. Maturitas. 2024; 189: 108055. https://dx.doi.org/10.1016/j.maturitas.2024.108055.
35. Javadpour S., Sharifi N., Mosallanezhad Z., Rasekhjahromi A., Jamali S. Assessment of premature menopause on the sexual function and quality of life in women. Gynecol. Endocrinol. 2021; 37(4): 307-11. https://dx.doi.org/10.1080/09513590.2021.1871894.
36. Yela D.A., Soares P.M., Benetti-Pinto C.L. Influence of sexual function on the social relations and quality of life of women with premature ovarian insufficiency. Rev. Bras. Ginecol. Obstet. 2018; 40(2): 66-71. https://dx.doi.org/10.1055/s-0037-1615289.
37. Blümel J.E., Chedraui P., Vallejo M.S., Dextre M., Elizalde A., Escalante C. et al. Genitourinary symptoms and sexual function in women with primary ovarian insufficiency. Climacteric. 2024; 27(3): 269-74. https://dx.doi.org/10.1080/13697137.2024.2306278.
38. Soman M., Huang L.C., Cai W.H., Xu J.B., Chen J.Y., He R.K. et al. Serum androgen profiles in women with premature ovarian insufficiency: a systematic review and meta-analysis. Menopause. 2019; 26(1): 78-93. https://dx.doi.org/10.1097/GME.0000000000001161.
39. Табеева Г.И., Марченко Л.А., Карселадзе А.И., Бутарева Л.А., Строганова А.М. Роль гена андрогенного рецептора в генезе преждевременной недостаточности яичников. Акушерство и гинекология. 2011; 6: 36-41.
40. Zheng J., Islam R.M., Skiba M.A., Bell R.J., Davis S.R. Associations between androgens and sexual function in premenopausal women: a cross-sectional study. Lancet Diabetes Endocrinol. 2020; 8(8): 693-702. https://dx.doi.org/10.1016/S2213-8587(20)30239-4.
41. Гависова А.А., Киндышева С.В., Стародубцева Н.Л., Франкевич В.Е., Долгушина Н.В. Андрогенный профиль у женщин с бесплодием в программах вспомогательных репродуктивных технологий в зависимости от овариального ответа. Акушерство и гинекология. 2022; 10: 129-37.
42. Davis S.R. Androgens in premenopausal women and women with premature ovarian insufficiency. Climacteric. 2021; 24(5):459-65. https://dx.doi.org/10.1080/13697137.2020.1866530.
43. Davis S.R., Wahlin-Jacobsen S. Testosterone in women—the clinical significance. Lancet Diabetes Endocrinol. 2015; 3(12): 980-92. https://dx.doi.org/10.1016/S2213-8587(15)00284-3.
44. van Zwol-Janssens C., Jiskoot G., Schipper J., Louwers Y.V. Introducing a value-based healthcare approach for women with premature ovarian insufficiency (POI): Recommendations for patient-centered outcomes in clinical practice. Maturitas. 2024; 184: 107971. https://dx.doi.org/10.1016/j.maturitas.2024.107971.
45. Meziou N., Scholfield C., Taylor C.A., Armstrong H.L. Hormone therapy for sexual function in perimenopausal and postmenopausal women: a systematic review and meta-analysis update. Menopause. 2023; 30(6): 659-71. https://dx.doi.org/10.1097/GME.0000000000002185.
46. Singer D., Mann E., Hunter M.S., Pitkin J., Panay N. The silent grief: psychosocial aspects of premature ovarian failure. Climacteric. 2011; 14(4): 428-37. https://dx.doi.org/10.3109/13697137.2011.571320.
47. Davis S.R., Baber R., Panay N., Bitzer J., Perez S.C., Islam R.M. et al. Global Consensus Position Statement on the use of testosterone therapy for women. J. Clin. Endocrinol. Metab. 2019; 104(10): 4660-6. https://dx.doi.org/10.1210/jc.2019-01603.
48. Achilli C., Pundir J., Ramanathan P., Sabatini L., Hamoda H., Panay N. Efficacy and safety of transdermal testosterone in postmenopausal women with hypoactive sexual desire disorder: a systematic review and meta-analysis. Fertil. Steril. 2017; 107(2): 475-482.e15. https://dx.doi.org/10.1016/j.fertnstert.2016.10.028.
49. Guerrieri G.M., Martinez P.E., Klug S.P., Haq N.A., Vanderhoof V.H., Koziol D.E. et al. Effects of physiologic testosterone therapy on quality of life, self-esteem, and mood in women with primary ovarian insufficiency. Menopause. 2014; 21(9): 952-61. https://dx.doi.org/10.1097/GME.0000000000000195.

Поступила 01.08.2024

Принята в печать 12.11.2024